The University of Chicago Header Logo

Connection

Urs C. Schmidt-Ott to Treatment Outcome

Back to Details
This is a "connection" page, showing publications Urs C. Schmidt-Ott has written about Treatment Outcome.
Urs C. Schmidt-Ott
Connection Strength
0.050
Treatment Outcome
  1. Intravitreal aflibercept 8 mg in neovascular age-related macular degeneration (PULSAR): 48-week results from a randomised, double-masked, non-inferiority, phase 3 trial. Lancet. 2024 Mar 23; 403(10432):1141-1152.
    View in: PubMed
    Score: 0.025
  2. Intravitreal aflibercept 8 mg in diabetic macular oedema (PHOTON): 48-week results from a randomised, double-masked, non-inferiority, phase 2/3 trial. Lancet. 2024 Mar 23; 403(10432):1153-1163.
    View in: PubMed
    Score: 0.025
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.